Pink16 Apr 2019 09:28
much of the debt is underwritten by AZN's loan facility, which is easily serviceable for CIR, who have multiple revenue streams on top of Tudorza - also, the sales decline is seen as a blip by most, whilst the FDA processes continued.
At these prices the company is hugely undervalued, although I don't see a huge re-rate until they clarify the funding package. A Sell it is not....